Majority of DVT Cases Treated in Single-Setting With Trellis-8 Catheter
From Bacchus Vascular, Reducing Patient Lytic Exposure, Bleeding
Complications and Treatment Cost
SANTA CLARA, Calif., March 6 /PRNewswire/ -- Bacchus Vascular Inc., a leading provider of innovative medical devices used by interventional radiologists, vascular surgeons and interventional cardiologists for the minimally invasive treatment of deep vein thrombosis (DVT) and other peripheral vascular disease, announced today that the Journal of Vascular Interventional Radiology (JVIR) has published a study comparing the clinical use of the Trellis-8 infusion catheter from Bacchus Vascular with conventional catheter-directed thrombolysis (CDT) in the treatment of DVT in its March 2008 issue.
Results of the study showed that Grade II and III lysis was achieved in 93% of patients treated with the Trellis catheter and 79% of patients treated with CDT even though thrombolytic doses and infusion durations were less with the Trellis catheter than with conventional CDT. Major hemorrhage was reported in none of the Trellis catheter patients and in 8.5% of patients treated with CDT. The per-patient cost of therapy was $3,697 for the Trellis catheter and $5,473 for CDT. This cost reduction is due to approximately 80% of the Trellis catheter patients being treated in the single-setting of the interventional suite with less time required for follow-up monitoring in a costly critical care unit compared with CDT patients.
The study, which was authored by Daniel E. Hilleman, PharmD (Department
of Pharmacy Practice, Creighton University School of Pharmacy, Omaha, NE)
and Mahmood K. Razavi, MD (Department of Vascular and Interventional
Radiology, Stanford University Hospital, Stanford, CA), compared
retrospectively collected data from 147 patients treated for DVT with the
Trellis-8 infusion catheter at 45 hospitals in the U.S. and three hospitals
outside the U
|SOURCE Bacchus Vascular Inc.|
Copyright©2008 PR Newswire.
All rights reserved